Assessing the Cardiovascular Risk Between Celecoxib and Nonselective Nonsteroidal Antiinflammatory Drugs in Patients With Rheumatoid Arthritis and Osteoarthritis : A 3-Year Nationwide Comparative Observational Study in Japan (ACCEPT)

• Hirayama Atsushi

  Division of Cardiology, Nihon University School of Medicine

• Tanahashi Norio

  Department of Neurology, Saitama Medical University, International Medical Center

• Daida Hiroyuki

  Department of Cardiovascular Medicine, Juntendo University

• Ishiguro Naoki

  Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine

• Chachin Motohiko

  Medical Affairs, Pfizer Japan Inc

• Sugioka Toshihiko

  Medical Affairs, Astellas Pharma Inc

• Kawai Shinichi

  Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine

• on behalf of all ACCEPT study investigators in Japan

書誌事項

タイトル別名

• Assessing the Cardiovascular Risk Between Celecoxib and Nonselective Nonsteroidal Antiinflammatory Drugs in Patients With Rheumatoid Arthritis and Osteoarthritis
• – A 3-Year Nationwide Comparative Observational Study in Japan (ACCEPT) –

抄録

Background: A prospective, 3-year comparative observational study compared the risk of cardiovascular events in patients with osteoarthritis or rheumatoid arthritis prescribed celecoxib or a nonsteroidal antiinflammatory drug (NSAID). Methods and Results: Patients prescribed celecoxib (n=5,470) or NSAIDs (n=5,059) between November 1, 2007, and July 31, 2008 in 1,084 hospitals and clinics in Japan were eligible for safety analysis. Mean (standard deviation) observation for the celecoxib group was 716 (420) days and 692 (426) days for the NSAID group (P=0.004). Composite I (adjudicated cardiovascular adverse events of myocardial infarction, angina pectoris, heart failure, cerebral infarction, cerebral hemorrhage) number of events (percentage) and rate/1,000 person years was 66 (1.2%) and 6.2 (10,745 person years), respectively, for the celecoxib and 65 (1.3%) and 6.8 (9,601 person years) for the NSAID (P=0.58) groups. Composite II (all cardiovascular events) number of events (percentage) and rate/1,000 person years was 79 (1.4%) and 7.4, respectively, for the celecoxib and 84 (1.7%) and 8.8 for the NSAID (P=0.26) group. Adjusted Cox hazards ratio (95% confidence interval) was 0.89 (0.63–1.27; P=0.52) for Composite I, 0.87 (0.63–1.19; P=0.39) for Composite II and 1.03 (0.75–1.41; P=0.87) for death from all causes. Conclusions: After adjustment for confounding variables, celecoxib was not associated with an increase of cardiovascular risk in comparison with nonselective NSAID in Japanese patients with rheumatoid arthritis or osteoarthritis in an observational setting.  (Circ J 2014; 78: 194–205)<br>

収録刊行物

• Circulation Journal

  Circulation Journal 78 (1), 194-205, 2014

  一般社団法人 日本循環器学会

キーワード

• Cardiovascular risk
• Celecoxib
• Nonsteroidal antiinflammatory drug (NSAID)
• Osteoarthritis
• Rheumatoid arthritis

詳細情報

• CRID: 1390001205109260160
• NII論文ID: 130003382167
• NII書誌ID: AA11591968
• DOI: 10.1253/circj.cj-12-1573
• COI: 1:CAS:528:DC%2BC2cXjt1yrs7g%3D
• ISSN: 13474820
• ISSN: 13469843
• NDL書誌ID: 025112639
• PubMed: 24152722
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I025112639
• Web Site: https://www.jstage.jst.go.jp/article/circj/78/1/78_CJ-12-1573/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2014247994
• 本文言語コード: en
• データソース種別:
  • JaLC
  • NDL
  • Crossref
  • PubMed
  • CiNii Articles
  • KAKEN
• 抄録ライセンスフラグ: 使用不可